<\/p>\n\n\n\n
One trace element, two sides \u2013 and what that means for our lives with Parkinson\u2019s<\/strong><\/p>\n\n\n\n When we talk about Parkinson\u2019s disease, most conversations naturally revolve around dopamine<\/strong>, movement<\/strong>, exercise<\/strong>, and medication<\/strong>. Iron<\/strong>, by contrast, rarely takes center stage. And yet this small trace element plays a central \u2013 and deeply paradoxical \u2013 role<\/strong> in human biology, particularly in the brain.<\/p>\n\n\n\n Iron is essential for life.<\/strong> But in the wrong place, or in excessive amounts, it can become harmful<\/strong>. Nowhere does this delicate balancing act become more visible than in Parkinson\u2019s disease.<\/p>\n\n\n\n <\/p>\n\n\n\n Iron accounts for only a tiny fraction of our total body weight. Despite this, life without iron is simply not possible. It is involved in countless processes that keep our cells, organs, and nervous system functioning.<\/p>\n\n\n\n Iron is crucial for oxygen transport<\/strong> via hemoglobin in red blood cells and energy production<\/strong> in the mitochondria, which are the \u201cpowerhouses\u201d of our cells. It is crucial for synthesis of neurotransmitters<\/strong>, including dopamine, serotonin, and norepinephrine, DNA repair and cell division<\/strong> and immune defense and resistance to infection<\/strong>.<\/p>\n\n\n\n When iron levels are too low, the consequences are often felt quickly: fatigue, weakness, reduced stamina, and difficulty concentrating<\/strong>. These are symptoms that many people with Parkinson\u2019s already struggle with \u2013 and iron deficiency can quietly amplify them.<\/p>\n\n\n\n <\/p>\n\n\n\n Although the brain makes up only about 2% of body weight, it consumes around 20% of the body’s oxygen. Iron is also essential here: it supports the transmission of nerve impulses<\/strong>, the formation of myelin<\/strong> \u2013 the protective sheath around nerve fibers \u2013 and it supports learning processes, memory, adaptability<\/strong> (neuronal plasticity), and dopamine production<\/strong>.<\/p>\n\n\n\n Hence, no iron means no dopamine.<\/strong> And yet, this is exactly where iron\u2019s darker side begins to emerge.<\/p>\n\n\n\n <\/p>\n\n\n\n Iron is chemically highly reactive. Its ability to switch between two states (Fe\u00b2\u207a and Fe\u00b3\u207a<\/strong>) allows it to drive vital biochemical reactions \u2013 but this same property also makes it potentially dangerous.<\/p>\n\n\n\n When iron is not tightly controlled, free iron can generate highly reactive oxygen radicals<\/strong>. Through the so\u2011called Fenton reaction<\/strong>, extremely aggressive hydroxyl radicals are formed. These molecules can damage almost everything they encounter, including DNA, cell membranes, mitochondria and proteins.<\/p>\n\n\n\n Under normal circumstances, the body neutralizes this risk by binding iron to storage and transport proteins such as ferritin<\/strong> and transferrin<\/strong>. With increasing age \u2013 and particularly in Parkinson\u2019s disease \u2013 this finely balanced system can begin to fail.<\/p>\n\n\n\n <\/p>\n\n\n\n A growing body of research shows a consistent pattern: In Parkinson\u2019s disease, brain iron accumulation<\/strong>, <\/strong>especially in the substantia nigra<\/strong><\/strong>, is increasingly recognized as a key pathological feature.<\/p>\n\n\n\n This region of the midbrain is exactly where dopaminergic neurons<\/strong>, crucial for smooth and coordinated movement, progressively degenerate.<\/p>\n\n\n\n Recent reviews and imaging studies confirm that:<\/p>\n\n\n\n \u26aaIron accumulation in the substantia nigra occurs early and progressively<\/strong><\/p>\n\n\n\n \u26aaHigher iron levels are associated with greater neuronal loss and more severe symptoms<\/strong><\/p>\n\n\n\n <\/p>\n\n\n\n A particularly compelling framework comes from the work of Rachel M. Wise and colleagues<\/strong>, based in Munich and New York. Their research highlights a toxic interaction at the heart of Parkinson\u2019s pathology:<\/p>\n\n\n\n Iron + dopamine + alpha\u2011synuclein = a neurotoxic environment<\/strong><\/p>\n\n\n\n Rachel M. Wise et al. describe how:<\/p>\n\n\n\n \u26aaIron accelerates the oxidation of dopamine<\/strong><\/p>\n\n\n\n \u26aaThis leads to the formation of highly reactive dopamine byproducts<\/strong><\/p>\n\n\n\n \u26aaAlpha\u2011synuclein misfolds more easily and aggregates<\/strong><\/p>\n\n\n\n Together, these processes likely explain why dopaminergic neurons are uniquely vulnerable<\/strong> in Parkinson\u2019s disease.<\/p>\n\n\n\n <\/p>\n\n\n\n As contradictory as it sounds, many people with Parkinson\u2019s disease simultaneously have low iron levels in their blood<\/strong>. This is very often combined with reduced appetite<\/strong>, constipation<\/strong> and slowed gastric emptying<\/strong>, impaired intestinal absorption<\/strong> and interactions with Parkinson\u2019s medications<\/strong>. <\/p>\n\n\n\n It is known, that Iron deficiency can worsen<\/strong> fatigue, physical and cognitive performance, susceptibility to infections and concentration and attention<\/strong>.<\/p>\n\n\n\n <\/p>\n\n\n\n Levodopa and entacapone are very commonly used medications for the treatment of Parkinson’s disease. Iron and levodopa share the same transport pathway in the intestine. When taken together, iron can bind to levodopa and significantly reduce its absorption<\/strong>.<\/p>\n\n\n\n Practical recommendation:<\/strong> To avoid interference with medication effectiveness, iron supplements or iron\u2011rich meals should be taken at least two hours apart from levodopa<\/strong>. This time separation helps ensure optimal absorption of levodopa and more stable symptom control.<\/p>\n\n\n\n Regarding entacapone<\/strong>, more recent research shows that it binds iron in the gut<\/strong>, may promote long\u2011term iron deficiency<\/strong> and may promote long\u2011term iron deficiency<\/strong>.<\/p>\n\n\n\n <\/p>\n\n\n\n Medications like deferiprone<\/strong> can remove excess iron from the brain. Clinical studies have demonstrated a measurable reduction in iron deposits<\/strong>. Despite this biological effect, however, no consistent clinical benefit<\/strong>, such as a clear and sustained improvement in symptoms, has yet been proven. Furthermore, some treated patients experienced significant side effects that may limit the use of such substances.<\/p>\n\n\n\n <\/p>\n\n\n\n My practical recommendations<\/strong> are as follows: Iron levels should be checked regularly<\/strong>, especially ferritin, hemoglobin, and transferrin saturation. When iron is obtained through diet, plant-based sources<\/strong> such as legumes, nuts, seeds, and dark green leafy vegetables are preferable. Combining iron supplements with vitamin C<\/strong> can improve absorption in the intestines. It is also important to always take iron separately from Parkinson’s medications<\/strong>, as it can interfere with their effectiveness. Iron supplements should not be used preventively or “just in case<\/strong>,” but only in cases of a clearly diagnosed deficiency and with a corresponding medical recommendation.<\/p>\n\n\n\n <\/p>\n\n\n\n When it comes to iron, the issue is not simply more<\/em> or less<\/em>. It is about location, timing, and balance<\/strong>. For people living with Parkinson\u2019s, this means:<\/p>\n\n\n\n \u26aaIron is essential<\/strong><\/p>\n\n\n\n \u26aaToo much<\/strong> iron<\/strong> in the brain can be harmful<\/strong><\/p>\n\n\n\n \u26aaToo little systemic iron<\/strong> can also be harmful, even while the brain shows iron accumulation.<\/p>\n\n\n\n The better we understand this dual role, the closer we come to truly individualized, safe, and effective care<\/strong>. And for me, both as a nurse and as someone who walks alongside people living with Parkinson\u2019s every day, iron has become a powerful reminder that this disease is rarely about simple answers \u2013 but about learning, again and again, to respect the fine balance our bodies are striving to maintain.<\/p>\n\n\n\n Further links: <\/p>\n\n\n\n \ud83d\udd17Nigrostriatal iron accumulation in the progression of Parkinson\u2019s disease<\/em> (Nature, 2025)<\/a><\/mark><\/p>\n\n\n\n \ud83d\udd17Iron Deposition in Parkinson\u2019s Disease: A Mini-Review<\/em> (Springer, 2024)<\/a> <\/mark><\/p>\n\n\n\n \ud83d\udd17Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson’s disease and Neurodegeneration with Brain Iron Accumulation disorders<\/em> (Neurobiology of Disease, 2022)<\/a><\/mark><\/p>\n\n\n\n \ud83d\udd17The Parkinson\u2019s disease drug entacapone disrupts gut microbiome homeostasis via iron sequestration<\/em> (Nature Microbiology, 2024)<\/a><\/mark><\/p>\n\n\n\n \ud83d\udd17FAIR PARK II study (NEJM). Trial of Deferiprone in Parkinson\u2019s Disease.<\/a><\/mark><\/p>\n\n\n\nWhy iron is indispensable for our bodies<\/strong><\/h3>\n\n\n\n
The Brain and Iron in Parkinson’s Disease: High Demand, High Vulnerability<\/strong><\/strong><\/strong><\/strong><\/h3>\n\n\n\n
Oxidative Stress: When Iron Becomes Harmful in Parkinson\u2019s<\/strong><\/h3>\n\n\n\n
Iron and Parkinson\u2019s: Focus on the Substantia Nigra<\/strong><\/h3>\n\n\n\n
A Dangerous Triangle: Iron, Dopamine, and Alpha\u2011Synuclein in Parkinson\u2019s Disease<\/strong><\/h3>\n\n\n\n
Iron <\/strong><\/mark><\/strong>Deficiency in Parkinson’s Disease<\/strong><\/mark><\/strong><\/h3>\n\n\n\n
Iron Interactions with Levodopa and Entacapone<\/mark><\/strong><\/h3>\n\n\n\n
Iron Chelation \u2013 Hope, but no Breakthrough<\/mark><\/strong><\/h3>\n\n\n\n
What does this mean for Everyday Life?<\/strong><\/h3>\n\n\n\n
My Conclusion: Balance instead of Extremes<\/mark><\/strong><\/h3>\n\n\n\n